PharmaSave
ActiveThe computed 12-month bankruptcy probability of PharmaSave is 1.5% (moderate). The 2025 annual accounts show equity of €11k and a net result of €667. Equity remains stable across the filed fiscal years (±1% per year). Its solvency ranks better than 67% of 10289 sector peers (fiscal year 2025). The company has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
65
/ 100
Healthy
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability46▼-6
Solvency80▼-5
Growth78=
Track record100
Bankruptcy probability, 12 months
1.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days acceptable
Liquidity ample (current ratio 3.1 against 6.06 in 2024; short-term debt: 32% and cash: 93.8% of total assets), and 45.3% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €11k
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-09-2026, 45 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 9 filingsDeviation from the deadline
2025
45 d late
2024
41 d early
2023
7 d early
2022
31 d late
2021
1 d early
2020
92 d early
2019
23 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
18-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
€8k
EBIT margin
9.9%
Net result
€667▼ 34.5%
2024 · €1k
2018: €594
2019: €302
2020: €525
2021: €-1k
2022: €-277
2023: €480
2024: €1k
2018 → 2025
Working capital
€13k▼ 4.7%
2024 · €14k
2018: €10k
2019: €10k
2020: €11k
2021: €9k
2022: €9k
2023: €11k
2024: €14k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€8k
Equity€9k-€9k▼ 3.1%€9k▲ 5.5%€10k▲ 11.0%€11k▲ 6.5%
Operating result€-404-€304€374▲ 23.3%€987▲ 164%€776▼ 21.4%
Net result€-1k-€-277▲ 81.2%€480€1k▲ 112%€667▼ 34.5%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 21% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €20k
Fixed assets
€178=
Current assets
€20k▲ 17.5%
Equity and liabilities €20k
Equity
€11k▲ 6.5%
Debt
€9k▲ 33.8%
The debt ratio rises from 39.7% to 45.3%. Equity and debt are higher.
Key figures and ratios
Solvency
54.7%▼
2024 · 60.3%
Current ratio
3.10▼
2024 · 6.06
Quick ratio
3.10▼
2024 · 6.06
Debt / equity
0.83▲
2024 · 0.66
ROE
6.1%▼
2024 · 9.9%
ROA
3.3%▼
2024 · 6.0%
Debt
€9k▲
2024 · €7k
Debt ≤ 1 year
€6k▲
2024 · €3k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€17k€20k▲
Fixed assets21/28€178€178=
Financial fixed assets28€178€178=
Current assets29/58€17k€20k▲
Amounts receivable within one year40/41€7k€1k▼
Trade receivables40€6k€0▼
Other amounts receivable41€600€1k▲
Cash at bank and in hand54/58€10k€19k▲
Equity and liabilities
Total equity and liabilities10/49€17k€20k▲
Equity10/15€10k€11k▲
Contributions10/11€12k€12k=
Profit (loss) carried forward14€-2k€-1k▲
Amounts payable17/49€7k€9k▲
Amounts payable within one year42/48€3k€6k▲
Trade debts44€2k€6k▲
Suppliers440/4€2k€6k▲
Other amounts payable47/48€717€0▼
Accrued charges and deferred income492/3€4k€3k▼
Income statement
Code20242025
Turnover70-€8k
Goods, raw materials, services and sundry goods60/61-€7k
Other operating charges640/8€387€417▲
Gross operating margin9900€1k€1k▼
Operating profit (loss)9901€987€776▼
Financial income75/76B€300€296▼
Recurring financial income75€300€296▼
Financial charges65/66B€268€405▲
Recurring financial charges65€268€405▲
Profit (loss) for the period before taxes9903€1k€667▼
Profit (loss) for the period9904€1k€667▼
Profit (loss) for the period to be appropriated9905€1k€667▼
Appropriation of the result
Profit (loss) to be appropriated9906€-2k€-1k▲
Profit (loss) brought forward from the previous period14P€-3k€-2k▲
The notes to these accounts (4 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
14-09
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 45 days late
2025
20-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2018net €1k ▲112%
Net result €1k, the highest in the series.
24-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Back to profitnet €480
Net result €480 after 2 loss-making years.
31-12
Financial
Liquidity quadruplescurrent ratio 16.74
Current ratio from 4.70 to 16.74; short-term debt falls from €2k to €717.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 31 days late
2022
30-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Weakest financial yearnet €-1k ▼382%
Net result drops to €-1k, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity triplescurrent ratio 21.71
Current ratio from 7.33 to 21.71; short-term debt falls from €2k to €439.
30-04
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
08-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
30-09
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 61 days late
2018
07-05
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Gillis (bij-Brussel) · 1 establishment unit since 2017
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Fonsnylaan 461060 Sint-Gillis (bij-Brussel)Ground area
3.6 ha
Building footprint
972 m²
Volume, LiDAR
8,820 m³
Parcel 21562A0435/02L002, Brussels · tallest building 20.6 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
Pharmasave
since 20172.265.683.834
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21562A0435/02L002 | Brussels | 3.6 ha | 1 · 972 m² | 20.6 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
DL PHARMA +
BE 0755.325.637
Zulte · Eq €11k
Apotheek DC Turnhout
BE 0436.019.057
Turnhout · Eq €11k
AJPhar
BE 0778.569.213
Waterloo · Eq €11k
ALBA2RO
BE 0738.728.937
Gembloux · Eq €11k
Pharmacie du Palais
BE 0899.955.508
Thimister-Clermont · Eq €11k
Of 5,223 companies in sector 47730 we hold annual accounts for 3,862. 880 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded30-06-2017
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.